EMA Restricts Sanofi's Lemtrada Use, Initiates Risk-Benefit Review
Executive Summary
Labeling changes for the multiple sclerosis drug being mandated by European regulators were made to the US label in January.
You may also be interested in...
EMA Recommends Caution For Pfizer's Xeljanz
The European Medicines Agency's drug safety committee has concluded that Pfizer's Xeljanz could increase the risk of blood clots in patients who are already at high risk. The committee has also recommended restrictions on the use of Sanofi's multiple sclerosis drug, Lemtrada.
Biogen, AbbVie Withdraw Struggling MS Drug Zinbryta Due To Safety Issues
Antibody was approved in the US with a liver safety warning while EU regulators recently limited the drug's use. Now, EMA has begun an urgent review of reports of inflammatory brain disorders related to Zinbryta.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.